1. Home
  2. ADEA vs DYN Comparison

ADEA vs DYN Comparison

Compare ADEA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adeia Inc.

ADEA

Adeia Inc.

N/A

Current Price

$12.84

Market Cap

2.6B

Sector

Technology

ML Signal

N/A

DYN

Dyne Therapeutics Inc.

N/A

Current Price

$15.48

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADEA
DYN
Founded
1990
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.8B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ADEA
DYN
Price
$12.84
$15.48
Analyst Decision
Buy
Strong Buy
Analyst Count
4
17
Target Price
★ $38.25
$34.33
AVG Volume (30 Days)
1.5M
★ 2.2M
Earning Date
11-02-2026
11-05-2026
Dividend Yield
★ 1.38%
N/A
EPS Growth
★ 73.68
N/A
EPS
★ 0.37
N/A
Revenue
★ $443,386,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.99
N/A
P/E Ratio
$39.05
★ N/A
Revenue Growth
★ 17.91
N/A
52 Week Low
$11.93
$14.00
52 Week High
$34.34
$27.31

Technical Indicators

Market Signals
Indicator
ADEA
DYN
Relative Strength Index (RSI) 24.07 38.49
Support Level N/A $14.43
Resistance Level $26.48 $19.48
Average True Range (ATR) 0.94 0.96
MACD -0.19 -0.21
Stochastic Oscillator 0.70 0.56

Price Performance

Historical Comparison
ADEA
DYN

About ADEA Adeia Inc.

Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: